Kodiak Sciences Inc - Company Profile
Powered by
All the data and insights you need on Kodiak Sciences Inc in one report.
- Save hours of research time and resources with
our up-to-date Kodiak Sciences Inc Strategy Report
- Understand Kodiak Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Kodiak Sciences Inc (Kodiak Sciences) is a clinical-stage biopharmaceutical company that develops therapies for the treatment of chronic and high-prevalence ophthalmic diseases. The company pipeline products includes KSI 301 an anti-VEGF biologic development, which offers wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy; KSI-501 an anti-IL6 and anti-VEGF bispecific biopolymer conjugate; and KSI-601 a triplet biopolymer conjugate, which treats dry age-related macular degeneration. Kodiak Sciences utilizes proprietary Antibody Biopolymer Conjugate (“ABC”) Platform, that combines biologics design with next generation phosphorylcholine biopolymers. It commercializes technology to both bio-pharmaceuticals and small molecules companies. The company operates in the US and Switzerland. Kodiak Sciences is headquartered in Palo Alto, California, the US.
Kodiak Sciences Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline Product: |
KSI 301: |
Retinal Vein Occlusion |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Kodiak Sciences Inc | Axsome Therapeutics Inc | Flexion Therapeutics Inc | Ocular Therapeutix Inc | Apoplogic Pharmaceuticals Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Palo Alto | New York | Burlington | Bedford | Aurora |
State/Province | California | New York | Massachusetts | Massachusetts | Colorado |
No. of Employees | 111 | 545 | 257 | 267 | - |
Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Victor Perlroth, MD | Chief Executive Officer; Chairman | Executive Board | 2009 | 49 |
John Borgeson | Senior Vice President; Chief Financial Officer | Senior Management | 2016 | 60 |
Michael S. Louie | Senior Vice President - Digital Transformation; Chief Information Officer | Senior Management | - | - |
Rezi Zawadzki | Vice President - Biometrics and Clinical Data Science | Senior Management | - | - |
Bernd Jandeleit | Vice President - Chemistry | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward